Safety, Tolerability Study of SG2000 in the Treatment of Advanced Chronic Lymphocytic Leukemia and Acute Myeloid Leukemia

Inclusion Criteria:

* male or female greater than or equal to 18 years of age
* have one of the following disease states: Acute Myeloid Leukemia (AML) (age \<60 years) with relapsed/refractory disease; •Chronic Lymphocytic Leukemia (CLL) with relapsed disease following a fludarabine-based regimen or relapsed disease following an alkylator-based regimen
* are recovered from the acute adverse effects of prior therapies (excluding alopecia and Grade ≤2 neuropathy).
* have blast counts that can be controlled by the use of hydroxycarbamide (500 to 3000 mg daily).
* have adequate hepatic function and renal function
* have an estimated life expectancy of \>3 months
* female subject must have a negative serum pregnancy result within 7 days before the start of the study; Both men and women must agree to use a medically acceptable form of contraception throughout the treatment period and for 3 months after discontinuation of treatment

Exclusion Criteria:

* are eligible for any standard therapy known to be life prolonging or life saving
* have diagnosis of AML French-American-British (FAB) classification (FAB) M3 (acute promyelocytic leukemia (APL))
* are receiving concurrent chemotherapy, radiotherapy, immunotherapy, biological or hormonal treatment for cancer.
* have undergone anticancer therapy including chemotherapy (except for hydroxycarbamide at a maximum daily dose of 3000 mg), endocrine therapy, immunotherapy, or the use of other investigational agents within 4 weeks before study entry.
* prior radiation therapy with volume of bone marrow treated over 25%.
* use of immunosuppressive therapy, including systemic steroids within 7 days before the first dose of SG2000.
* hyperleukocytosis (blast counts \>30 000/mm3).
* history of allogeneic stem cell or solid organ transplantation.
* positive serology for human immunodeficiency virus (HIV), hepatitis B or hepatitis C or have HIV-AIDS, or active hepatitis B or C.
* history of other invasive malignancy within 3 years except for cervical carcinoma in situ, nonmelanomatous carcinoma of the skin or ductal carcinoma in situ of the breast that has been surgically cured.
* have any coexisting medical condition that will substantially increase the risk associated with the subject's participation in the study.
* have psychiatric disorders or altered mental status precluding understanding of the informed consent process and/or completion of necessary studies.
* have persistent Grade 2 or greater toxicities from any cause (except alopecia or peripheral neuropathy).
* are pregnant or breast-feeding.